Search

Displaying results 2331 - 2340 of 7452 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever.

    Categories: Antihistamines for Systemic Use
  3. Drug

    Nitrogen

    go.drugbank.com/drugs/DB09152
    ApprovedInvestigationalVet approved

    Liquid nitrogen is used principally in cryotherapy for removal of diseased skin.

  4. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefit...

    Categories: Antihypertensive Agents Indicated for Hypertension
  6. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [L47870] DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.[A261080, A261085]

  7. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    Microdystrophin is a truncated, functional form of dystrophin. … Dystrophin is an essential protein responsible for muscle function; thus, patients with DMD experience a progressive deterioration of muscle mass and function.

  8. Drug

    Beroctocog alfa

    go.drugbank.com/drugs/DB14473
    ApprovedInvestigational

    Mixtures: ALPHANATE FOR INJECTION 250 iu/vial, ALPHANATE FOR INJECTION 1000 iu/vial
  9. Drug

    Donepezil

    go.drugbank.com/drugs/DB00843
    ApprovedInvestigational

    [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. … Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.

  10. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.